Pfizer will buy King Pharmaceuticals for $3.6B

October 12, 2010 By Marley Seaman , AP Health Writer
In this Jan. 25, 2009 file photo, Pfizer's world headquarters is shown in New York. Pfizer Inc., the world's largest pharmaceutical company by revenue, said Tuesday, Oct. 12, 2010, it will buy pain drug maker King Pharmaceuticals Inc. for $3.6 billion in cash. (AP Photo/Mark Lennihan, File)

(AP) -- Pfizer Inc. said Tuesday it will buy a company specializing in pain drugs in a $3.6 billion deal meant to shore up the portfolio of the world's largest drug company.

The deal to by King Pharmaceutical Inc. is Pfizer's largest since it bought rival Wyeth for $68 billion in 2009. Pfizer already has a large stake in the pain drug market with its drugs Lyrica and Celebrex, which combined for more than $5 billion in sales in 2009. But now the company is betting that King's work on "abuse-resistant" pain drugs will pay off and help make up for the revenue it will lose when top sellers such as the Lipitor no longer have patent protection in a few years.

King markets one such drug, called Embeda, and it's seeking approval for two others under the names Remoxy and Acurox. Embeda and Remoxy are similar to Purdue Pharma LP's , the top-selling painkiller in the U.S. All three are designed to treat pain by slowly releasing the narcotic . But the time-release mechanism on OxyContin can be defeated if the drug is crushed or dissolved, allowing users to get a high similar to what they can get from heroin.

Millions of people have reported abusing prescription painkillers including OxyContin in recent years, and regulators and health officials have pushed hard to get OxyContin alternatives on the market. Embeda and Remoxy are designed to be tougher to abuse, and so is Acurox, which is faster-acting. Embeda was approved in September 2009, but sales have been slow. The has held up approval of Remoxy and Acurox, partly because it wants more proof they will really cut down on abuse.

King plans to file a new application for approval of Remoxy in the fourth quarter of 2010 and one for Acurox in the first quarter of 2011.

Pfizer is paying $14.25 per share for King. That's a premium of 40 percent to the stock's Monday closing price of $10.15. Along with the abuse-resistant pain drugs, the deal gives Pfizer other products, including EpiPen, a pre-filled injection designed to quickly treat serious allergic reactions; Thrombin-JMI, designed to control bleeding; the Flector pain patch; and the pain drug Avinza.

Through a partnership with the U.S. Department of Defense, King also makes pre-filled injections designed to block the effects of nerve agents. The company also has an animal health business that will be combined with the unit Pfizer already owns.

King has struggled in recent years as patents on several of its key drugs have expired or been thrown out. The company reported a 17 percent drop in sales in the second quarter of this year.

The boards of both companies approved the deal. Pfizer said the purchase will add about 2 cents per share to its net income in 2011 and 2012, and 3 to 4 cents per share in each of the next three years. It does not expect the deal to affect its 2010 results. The company currently expects to earn $2.10 to $2.20 per share on revenue of about $68 billion.

The companies did not say whether jobs would be eliminated after the deal closes. King says it has about 2,600 employees. Pfizer had 116,500 workers at the end of 2009, but is in the process of cutting about 20,000 jobs in the wake of the Wyeth deal.

In midday trading, King shares soared 39 percent, or $3.99, to $14.14 and peaked at $14.17, a three-year high. shares rose 5 cents to $17.43.

Acurox was developed by Acura Pharmaceuticals Inc., which licensed it to King. The company will get royalties on sales if the drug is approved, and Acura shares rose 15 cents, or 6.6 percent, to $2.42.

shares

Related Stories

Recommended for you

Best of Last Year—The top Medical Xpress articles of 2017

December 20, 2017
It was a good year for medical research as a team at the German center for Neurodegenerative Diseases, Magdeburg, found that dancing can reverse the signs of aging in the brain. Any exercise helps, the team found, but dancing ...

Pickled in 'cognac', Chopin's heart gives up its secrets

November 26, 2017
The heart of Frederic Chopin, among the world's most cherished musical virtuosos, may finally have given up the cause of his untimely death.

Sugar industry withheld evidence of sucrose's health effects nearly 50 years ago

November 21, 2017
A U.S. sugar industry trade group appears to have pulled the plug on a study that was producing animal evidence linking sucrose to disease nearly 50 years ago, researchers argue in a paper publishing on November 21 in the ...

Female researchers pay more attention to sex and gender in medicine

November 7, 2017
When women participate in a medical research paper, that research is more likely to take into account the differences between the way men and women react to diseases and treatments, according to a new study by Stanford researchers.

Drug therapy from lethal bacteria could reduce kidney transplant rejection

August 3, 2017
An experimental treatment derived from a potentially deadly microorganism may provide lifesaving help for kidney transplant patients, according to an international study led by investigators at Cedars-Sinai.

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.